Recipe Scaling with Potency: Meaning, Evidence and Controls
Scale an approved formula, translate lot-specific potency into ingredient charges, and preserve a reviewable connection between the calculation and the batch actually made.

On this page · 11 sections
- 1Scaling and correction are two different things
- 2Scaling rules: proportional, fixed and step-fixed components
- 3The scaling → correction order
- 4Worked example: 100 kg master to 500 kg control
- 5Counter-balance excipient: an approved residual, not a free adjustment
- 6Two further cases: basis conversion and mixed-lot charging
- 7US drug and dietary-supplement requirements, kept in scope
- 8From approved calculation to reconstructable batch evidence
- 9Interfaces and recovery when inputs or execution change
- 10Failure modes and the controls that expose them
- 11Implementation and independent-review checklist
How does Recipe Scaling with Potency apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01Scaling and correction are two different things
Recipe scaling with potency is the calculation of ingredient charge quantities for a specified batch size using component-specific scaling rules and lot-specific potency expressed on the formula’s defined active-equivalent basis.
The batch-size question establishes the required quantity under each component’s scaling rule. The potency question then translates a required active-equivalent quantity into the physical mass of a selected material lot. These are separate decisions: changing batch size changes the target; changing lot potency changes the charge needed to meet that target.
Active equivalent means the formula’s defined measure of contribution, whether a named chemical moiety or a specified activity unit. The numerical examples below use mass equivalents, distinguishing active-equivalent mass from the material mass actually weighed.
| Concept | Question answered | Calculation output | Boundary |
|---|---|---|---|
| Recipe scaling with potency | What quantities deliver the defined composition at the chosen size? | Lot-specific charges | Combines scaling and potency translation |
| Proportional recipe scaling | How do nominal quantities change with batch size? | Scaled nominal quantities | Does not resolve lot potency |
| Moisture-correction-charge | How does an authorised moisture adjustment affect a charge? | Basis-adjusted quantity | One possible input to the wider calculation |
| As-is-vs-anhydrous-basis | What denominator does an assay use? | Interpreted potency basis | Does not itself select batch size |
| Overage | What intentional additional quantity does the formula specify? | Separately identified additional amount | Not a synonym for potency correction |
02Scaling rules: proportional, fixed and step-fixed components
Before applying assay arithmetic, assign each component an approved scaling rule and quantity basis: physical material mass, active-equivalent quantity, or a separately defined process quantity. These are formulation-control conventions, not interchangeable calculation options. Record the rule’s operating range and justification alongside the reference formula.
| Rule | Nominal quantity | Assumption to document |
|---|---|---|
| Proportional | Reference quantity × target batch size ÷ reference batch size | Use compatible units and matching batch-size definitions: do not compare a reference input mass with a target finished yield. |
| Fixed | The authorised amount, unchanged within its stated operating range | Identify what remains fixed and justify its suitability throughout that range. |
| Step-fixed | Approved amount per event × applicable event count | Define the event, such as an authorised transfer or vessel charge, and record how the target execution determines its count. |
A fixed physical mass preserves the material amount, not necessarily its active contribution. A fixed active-equivalent quantity preserves the intended active contribution; its physical charge can change with lot potency. Keep that distinction visible when passing quantities into the assay-adjusted charge calculation.
For a fixed quantity retained in the batch, its relative concentration decreases as batch size increases and increases as batch size decreases, on the declared quantity basis. Fixed status therefore needs formulation justification; it is not a convenient exemption from scaling.
Treat the counter-balance excipient as a residual governed by its own approved rule, not as another proportional ingredient. Its final quantity follows the other component calculations.
Mathematical composition scaling does not establish equivalent mixing, heat transfer, shear, addition behaviour, equipment loading, or product performance. Those process questions need their own established operating conditions and evidence.
03The scaling → correction order
The following sequence is calculation practice under declared formulation assumptions, not a universal regulatory formula. First define the target: total charged mass, dry-solids mass, volume, unit count and expected saleable output are different bases. The main example uses total charged mass; process losses remain outside that example. Do not substitute an output target for an input-mass target without a separately defined conversion.
Let B be target batch mass and B_ref reference batch mass, both in kg; k = B / B_ref is dimensionless. Let m_ref be reference active-material mass in kg. Let p_ref be its reference active-equivalent potency and p_lot the selected lot’s normalised active-equivalent potency, both in kg target active equivalent per kg material. These are mass fractions, not unconverted percentage values.
For a proportional active line, calculate q_target = k × m_ref × p_ref, in kg target active equivalent. Then calculate m_charge = q_target / p_lot, in kg material, using a positive p_lot. This preserves the reference formula’s actual potency assumption rather than treating its active-material charge as pure active. Fixed and step-fixed lines retain their previously assigned scaling rules.
Resolve the assay denominator and analyte identity once. Multiply a dry-basis assay by the applicable dry fraction only when needed to obtain as-issued potency; see as-is versus anhydrous basis. Do not substitute LOD for water without a defined analytical basis for water/LOD compensation. Apply a salt-to-active or other equivalence factor only when the reported analyte differs from the formula’s target analyte. An assay already expressed on the required as-is active-equivalent basis needs neither an additional drying adjustment nor a repeated equivalence factor.
Retain the reported assay, its units and basis, each authorised transformation, and the resulting normalised potency as separate values. Reject unresolved or dimensionally incompatible inputs rather than guessing a correction convention. Then allocate qualified lots, solve the approved counterbalance excipient, assess precision and feasibility, and submit the resulting charge plan for review. Keep unrounded calculation values distinct from executable weighing quantities so the reviewer can trace any rounding effect.
- Select revisionIdentify target basis and authorised component rules.
- Select lotsBind certificate revisions to available material quantities.
- Normalise PotencyResolve assay basis into compatible active-equivalent units.
- Calculate ChargesApply scaling rules, allocate lots and solve balancing mass.
- Review feasibilityAssess composition bounds, precision and proposed charges.
- Execute approved planCapture actual weights against the reviewed calculation.
- Reconcile differencesInvestigate discrepancies and record the authorised disposition.
04Worked example: 100 kg master to 500 kg control
All quantities below are illustrative calculation assumptions, not a recommended manufacturing formula or an established tolerance. The reference batch contains 100 kg of total charged material; the target contains 500 kg. The reference active material represents 100% active equivalent. The selected production lot has 96% potency on the required as-issued basis, so no further basis correction is applied.
Assume the active-equivalent target and binder scale proportionally. The fixed component remains unchanged per batch. The transfer component is step-fixed: the reference uses one transfer, while the target execution has two authorised transfers at 0.200 kg per transfer. The balancing excipient is assumed approved for residual adjustment within this example.
- Batch multiplier: k = 500 / 100 = 5.
- Target active equivalent: 2.000 × 5 = 10.000 kg.
- Production-lot charge: 10.000 / 0.96 = 10.416666… kg.
- Binder: 5.000 × 5 = 25.000 kg; fixed component: 0.500 kg; transfer component: 2 × 0.200 = 0.400 kg.
| Component | Scaling rule | Reference mass, kg | Target before lot correction, kg | Target after correction, kg, rounded for display |
|---|---|---|---|---|
| Active material | Proportional active equivalent | 2.000 | 10.000 | 10.417 |
| Binder | Proportional physical mass | 5.000 | 25.000 | 25.000 |
| Fixed component | Fixed physical mass | 0.500 | 0.500 | 0.500 |
| Transfer component | Step-fixed physical mass | 0.200 | 0.400 | 0.400 |
| Balancing excipient | Approved residual | 92.300 | 464.100 | 463.683 |
| Total | Not applicable | 100.000 | 500.000 | 500.000 |
Before lot correction, the balancing quantity is 500 − 10 − 25 − 0.500 − 0.400 = 464.100 kg, not 92.300 × 5 = 461.500 kg. The fixed and step-fixed lines do not follow the proportional multiplier. Multiplying the reference excipient blindly would therefore leave the target mass short.
After correction, the unrounded counter-balance excipient result is 500 − 25 − 0.500 − 0.400 − 10.416666… = 463.683333… kg. It is positive; approval of the adjustment remains a separate formulation assumption, not a conclusion drawn from that sign.
Two checks address different quantities. The total-mass check adds all corrected physical charges to exactly 500 kg. The active-equivalent check uses the unrounded charge: (10.000 / 0.96) × 0.96 = 10.000 kg. Passing the mass check alone would not demonstrate the intended active quantity.
Display rounding is not dispensing approval. If 10.417 kg were actually charged at 96% potency, it would deliver 10.00032 kg active equivalent: 0.00032 kg, or 0.32 g, above the calculated target. The example establishes no acceptance limit for that difference. The displayed active and excipient masses still sum with the other components to 500.000 kg, illustrating why rounded mass reconciliation cannot replace an active-equivalent check. Actual dispensing precision belongs in the approved weighing and dispensing controls.
05Counter-balance excipient: an approved residual, not a free adjustment
In the proposed control design, designate an explicitly approved counter-balance excipient and its adjustment rule before calculating the residual. A mathematically available filler is not automatically an authorised formulation variable. Approval should identify the component, permitted adjustment range and conditions under which balancing is appropriate.
m_balance = B − the sum of all other as-issued charge masses.
Here, B retains the target basis established above: the total as-issued charge mass being balanced, in the same mass unit as every term subtracted. Use the other components’ calculated physical charge masses, not their active-equivalent quantities. Finished yield and final volume are not interchangeable with B; in-process reconciliation addresses material accounting at the relevant processing stage.
Evaluate the residual against nonnegativity, applicable approved composition bounds and the excipient’s functional role. A positive balance can still produce an unsuitable concentration, impair manufacturability or change product performance. Assess any composition limit using its approved denominator rather than assuming that total charged mass is always the relevant basis.
If the residual is negative or outside an authorised bound, stop the proposed charge plan for formulation review. Do not conceal the conflict by clipping the excipient mass, lowering the active target or distributing the deficit across unrelated ingredients.
Where several components are adjustable, define enough additional approved constraints to obtain a determinate solution—for example, a specified ratio or an adjustment priority with explicit limits. An unconstrained solver should not invent the formulation.
This mass residual is not an instruction to adjust to final volume or another process endpoint. Such instructions need their own relevant density, temperature, endpoint or process basis rather than substitution into this mass equation.
06Two further cases: basis conversion and mixed-lot charging
Case: dry-basis salt assay to incoming charge
Assume an assay of 98.0% salt on a dry basis, an applicable water fraction of 2.0%, and a specified dry denominator that excludes that water. The hypothetical approved equivalence factor is 0.800 kg active equivalent per kg assayed salt. The required active equivalent is 7.6832 kg. These are illustrative inputs, not properties of a named chemical.
Applying the basis treatment established above, normalised potency is 0.980 × 0.980 × 0.800 = 0.76832 kg active equivalent per kg incoming material. The first factor represents assay; the second represents dry fraction. Their identical numerical values are coincidental. The dry-weight basis and salt-to-base conversion factor each enter once.
| Quantity | Calculation or assumption | Result | Unit |
|---|---|---|---|
| Dry-basis salt assay | Illustrative assay | 0.980 | kg salt per kg dry material |
| Dry fraction | Water-adjusted fraction | 0.980 | kg dry material per kg incoming material |
| Equivalence factor | Illustrative approved factor | 0.800 | kg active equivalent per kg salt |
| Normalised potency | Product of the preceding factors | 0.76832 | kg active equivalent per kg incoming material |
| Target active equivalent | Formula target | 7.6832 | kg |
| Incoming charge | Target divided by normalised potency | 10.000 | kg |
Thus, required incoming mass is 7.6832 / 0.76832 = 10.000 kg. This is the physical charge, not the mass of active equivalent.
Case: inventory-constrained allocation across two lots
Retain the main example’s 500 kg total charged mass and 10.000 kg active-equivalent target. Retain its already-scaled proportional binder at 25 kg, fixed component at 0.500 kg, and step-fixed component at 0.400 kg. Assume both active lots have potency on the required basis and are approved for this allocation. Lot A has 6.000 kg available at 0.950 kg active equivalent per kg material; lot B has sufficient inventory at 0.860 kg/kg.
Allocate all 6.000 kg of A: 6.000 × 0.950 = 5.700 kg active equivalent. The remaining target is 10.000 − 5.700 = 4.300 kg; B therefore supplies 4.300 / 0.860 = 5.000 kg of material.
| Lot | Normalised potency, kg/kg | Material charge, kg | Active equivalent, kg |
|---|---|---|---|
| A | 0.950 | 6.000 | 5.700 |
| B | 0.860 | 5.000 | 4.300 |
| Total | Not applicable | 11.000 | 10.000 |
Recompute the approved balancing excipient: 500 − 25 − 0.500 − 0.400 − 11.000 = 463.100 kg. This residual is nonnegative; its acceptability remains subject to the formulation controls covered above. Preserve each lot’s charge and active-equivalent contribution in the allocation and lot genealogy, rather than replacing them with an undocumented blended assay.
07US drug and dietary-supplement requirements, kept in scope
The calculation methods above are industry practice, not statutory formulas. The provisions below are binding US law within their stated product scope. Keep the authority for an obligation separate from the calculation evidence used to implement it.
- Binding law: the scoped formulation and record obligations mapped below.
- Official guidance: agency recommendations, distinct from binding provisions; no guidance recommendation is mapped here.
- Industry practice: the scaling, potency-correction and reconciliation methods described above.
- Software design criteria: implementation choices supporting those methods, not independent legal authority or proof of compliance.
The related calculation evidence column gives practical implementation connections, not additional statutory wording or a prescribed calculation format.
| Jurisdiction and product | Binding provision | Record or formulation obligation | Related calculation evidence |
|---|---|---|---|
| US finished drug products under 21 CFR Part 211 | 21 CFR 211.101(a) | Requires formulation with the intent to provide not less than 100 percent of the labeled or established active-ingredient amount. | Practical connection: link the active-equivalent target to the calculated component charge. |
| US finished drug products under 21 CFR Part 211 | 21 CFR 211.186(a) | Requires master production and control records for each drug product, including each batch size, prepared, dated and signed by one person and independently checked, dated and signed by a second person. | Practical connection: associate the batch-size calculation and independent review with the applicable master record. |
| US dietary supplements under 21 CFR Part 111 | 21 CFR 111.210(a) | Requires the master manufacturing record to include the supplement name and each dietary ingredient’s strength, concentration, weight or measure for each batch size. | Practical connection: map calculated ingredient quantities to the named product and batch size. |
| US dietary supplements under 21 CFR Part 111 | 21 CFR 111.210(e) | Requires the master manufacturing record to state any intentional dietary-ingredient overage amount. | Practical connection: identify any intentional overage separately in the calculation record. |
For record context, see US drug manufacturing controls and the dietary-supplement master manufacturing record. For other food products, devices, chemicals and non-US markets, consult the applicable product-specific rules rather than extending these US drug and supplement provisions.
08From approved calculation to reconstructable batch evidence
Use this proposed traceability model as manufacturing practice, not a database specification or software capability claim. Stable identifiers connect the calculation to its batch record and preserve the relationships below.
| Record | Reconstruction links |
|---|---|
| Calculation revision | Formula revision, component-rule versions, selected lot IDs and certificate revisions |
| Review decision | Calculation revision, reviewer, timestamp, decision and rationale |
| Dispense event | Approved calculation revision, batch, component, lot, operator, timestamp, mass and unit |
Preserve reported assay values and their basis to answer what the laboratory reported; retain normalised potency separately to show the usable active equivalent per mass charged. Keep unrounded calculations for mathematical reconstruction, rounded planned charges for dispensing instructions, and actual dispensed masses for execution comparison.
Proposed lifecycle: draft → reviewed → approved → partially executed → reconciled. Draft-to-reviewed freezes calculation inputs; reviewed-to-approved freezes the authorised charge plan. Changed formula rules, target size, lot allocation, certificate values or rounding rules trigger a new calculation revision and review. Mark replaced revisions superseded without deleting them. After partial execution, retain existing dispense events and resolve discrepancies through in-process reconciliation before marking the run reconciled.
Name these roles in the operating procedure: formulation owner for formula rules; QC scientist for assay-basis interpretation; independent calculation reviewer; dispensing operator; and authorised quality representative for discrepancy disposition.
Assign calculation approval to an authorised calculation approver, batch disposition to authorised quality personnel, and product release to authorised release personnel as separate decisions. Successful arithmetic supports review; release remains a separate authorized decision.
Formula Revision
Defines the controlled reference.
- recipe_id
- revision_id
- reference_batch_mass
- mass_unit
- target_mass_basis
Component Rule
Defines permitted scaling and balancing.
- component_id
- quantity_basis
- scaling_mode
- rule_parameters
- balance_authorisation_id
- balance_bounds
Lot Basis
Connects assay to normalised potency.
- lot_id
- certificate_revision
- assay_value
- assay_unit
- assay_basis
- basis_adjustments
- normalised_potency
Calculation Run
Preserves inputs and proposed charges.
- calculation_id
- formula_revision_id
- target_mass
- lot_allocations
- unrounded_masses
- rounded_masses
- supersedes_id
Execution and Review
Links actual charges and decisions.
- dispense_id
- calculation_id
- lot_id
- actual_mass
- mass_unit
- reviewer_id
- disposition
09Interfaces and recovery when inputs or execution change
Recommended interface responsibilities are design choices, not product capabilities: planning systems contribute batch targets and inventory context; laboratory or certificate records contribute lot-specific assay metadata; execution systems contribute weighed quantities and event identifiers. Define ownership across planning interfaces and laboratory interfaces, including who resolves conflicting values.
Before accepting inputs, check material and lot identity, unit compatibility, assay basis, certificate revision, formula revision, inventory availability and calculation status. Reject mismatches rather than silently substituting defaults.
- Before approval: preserve the prior calculation, record the changed input and revision reason, and generate a replacement draft.
- After approval but before dispensing: block use of superseded quantities and route the revised calculation for approval; retain the approved predecessor.
- After partial dispensing: retain the actual weighed masses, the certificate version and the original calculation as historical records in the batch execution history. If an accepted certificate revision changes potency, the weighed mass stays fixed but its active-equivalent contribution does not: reassess the active already charged at the accepted revised potency, distinguish staged material from material already charged, then recalculate the remaining requirement and balancing mass and assess whether an authorised completion path still exists.
Hypothetical worked case. A batch needs 10.000 kg of active on the approved target basis. The original certificate reported 98.0% potency on that basis, so the approved charge plan was 10.000 ÷ 0.980 = 10.204 kg of material. After 6.000 kg had been charged, an accepted certificate revision reported 96.0%. The charged material now contributes 6.000 × 0.960 = 5.760 kg of active, not the 5.880 kg originally estimated. The remaining requirement is 10.000 − 5.760 = 4.240 kg of active, or 4.240 ÷ 0.960 = 4.417 kg of material from that lot. Continuing the superseded plan would have added only 4.204 kg of material (4.036 kg active) and delivered 9.796 kg in total. Any counterbalance excipient mass must then be recalculated against the revised component masses, and the change must pass review before any further dispensing.
For duplicate messages or unavailable interfaces, use stable transaction identifiers, explicit pending states and controlled reconciliation against recorded execution. A successful retransmission should acknowledge the original transaction, not create a second dispense event. Resolve uncertain posting status before retrying physical work. Route an infeasible revised plan to an authorised hold or disposition workflow, not an improvised compensating addition.
10Failure modes and the controls that expose them
These practice-based checks help reviewers diagnose an assay-adjusted charge before execution.
| Warning sign | Likely error | Preventive or detective control | Responsible review role. |
|---|---|---|---|
| Active target changes by the scale factor twice | Already-scaled quantity reused as a reference | Retain reference and target quantities with distinct field names | Formula reviewer |
| Plausible assay attached to the wrong charge | Material or lot identity mismatch | Match identifiers across certificate and allocation | Materials reviewer |
| Mixed-lot result depends on a simple mean | Potencies averaged without mass weighting | Reconstruct active contribution by lot | Calculation reviewer |
| Unexplained discontinuity after rescheduling | Stale step-event count | Reconcile the event plan with component rules | Production reviewer |
| Displayed totals agree but reconstructed totals do not | Rounding or unit conversion applied inconsistently | Recalculate from retained values | Calculation reviewer |
Block calculation for missing, nonpositive, nonfinite or dimensionally incompatible potency inputs; do not silently substitute defaults. Separate these malformed or unusable inputs from mathematically valid values that still need specification review. Apply the basis treatment and counterbalance controls above. Route input changes through change control as appropriate to their impact.
11Implementation and independent-review checklist
Use this practice checklist to record acceptance decisions, not merely completed calculations.
- Basis accepted: target basis approved, reference potency explicit and lot basis resolved.
- Scaling accepted: proportional, fixed and step-fixed component rules justified.
- Charges accepted: allocation feasible; balancing rule authorised with a nonnegative residual; precision and rounding assessed.
- Traceability accepted: evidence linked, execution reconciled through in-process reconciliation, and reviewer decision recorded.
Maintain a small calculation test set covering matching reference and lot potency, changed batch size, cases immediately below and at a step-event boundary, the worked basis conversion, mixed-lot allocation, an infeasible residual, incompatible units and a changed certificate revision. Include rejection or reassessment outcomes where appropriate, rather than expecting every case to produce executable charges.
For each test, retain expected inputs, expected outputs, acceptance reasoning and the reviewed result. Equation checks establish arithmetic behaviour, not manufacturing-process suitability. Ask another qualified reviewer to reproduce the proposed charges without undocumented spreadsheet assumptions or an operator’s memory.
Handover criterion: the execution record identifies the approved calculation revision, and the batch execution history preserves any difference between planned and actual charges.
Frequently asked questions
Q.What changes if the requested batch size means saleable output rather than total charged mass?+
Treat saleable output as the planning endpoint, not the quantity to distribute across recipe lines. First establish the relationship between charged mass and recoverable product using an approved, process-specific yield assumption. Account separately for retained samples, rejected units, packaging losses and material that never enters the product. Then calculate ingredient targets for the resulting manufacturing quantity. A single yield factor is unsuitable where losses selectively remove active material. See yield-adjusted batch size.
Q.Can an assay specification range replace a lot-specific result in the calculation?+
A specification range describes acceptance boundaries; it does not identify the potency of the lot being dispensed. Using its midpoint or lower limit as though it were measured can systematically misstate the charge. Prefer an applicable, approved lot-specific result with its reporting basis and units. If the manufacturing procedure permits another basis, document that rule and its justification rather than silently substituting a value. Address uncertainty separately through measurement uncertainty in potency assay.
Q.What should happen when a revised certificate arrives after some material has already been weighed?+
Pause affected dispensing and addition while the revision is assessed. Preserve the original calculation, certificate version and actual weighed quantities; distinguish staged material from material already charged. Recalculate the remaining requirement using the accepted revised result and the potency contribution of material already added. Reassess any balancing excipient and dispensing instructions before proceeding. If the revised calculation implies excess active already present, escalate for disposition rather than issuing a negative addition. Preserve the decision in the batch execution history.
Q.How does potency reported in activity units per gram enter a mass-based recipe?+
Express the batch target in the same activity units as the lot result, then divide target activity by activity per gram to obtain grams of material. Confirm that the assay method, reference and unit definition are compatible with the formula target; similarly named activity units are not necessarily interchangeable. Keep activity and mass as separate quantities throughout the calculation. A mass percentage alone cannot substitute for biological activity without an established relationship. See relative potency bioassay.
Q.When does rounding require a different balance or dispensing strategy rather than a different formula target?+
Change the measurement approach when the rounded charge cannot meet the approved dispensing tolerance with suitable measurement capability. Display resolution alone does not establish that capability. Evaluate the balance at the intended net load, including tare conditions and uncertainty. Options include a more suitable balance or an approved, characterized premix whose carrier is included in the mass balance. Do not shift the active target merely to obtain convenient digits. See balance capability versus tolerance.
Q.How should fixed and step-fixed additions be treated when only part of a planned batch is manufactured?+
Rebuild the charge plan around the actual manufacturing scope. Proportional components follow the revised quantity; fixed additions remain tied to their defined event, such as one vessel preparation; step-fixed additions follow the number of qualifying cycles or sub-batches. Do not prorate every line by the fraction completed. Establish which additions have already occurred and whether they entered product or remained outside it. Confirm that the smaller run remains within approved processing conditions through change control.
Q.What does a potency above the formula’s nominal reference mean for the required material charge?+
For an unchanged active target, higher usable potency generally means less source material: multiply the nominal charge by reference potency divided by lot potency. Put both potencies on the same basis, applying any assay, water, loss-on-drying or salt conversion once only. Higher potency does not itself establish lot acceptability. If total charged mass is held constant, allocate the difference only to an approved, compatible, nonnegative counterbalance excipient; do not redistribute it indiscriminately across other ingredients.
Q.How should the potency-corrected charge plan be reconciled when actual manufacturing yield differs from the plan?+
Keep the approved charge plan as the baseline and reconcile actual net additions, returns, samples, waste and recovered product against it. Separate material-accounting differences from changes in concentration: lower recovered mass does not establish how much active was lost. Use relevant process observations and testing to assess that question. Do not retroactively change the potency factor to make yield appear correct, or calculate a top-up from yield alone. Document unexplained differences through yield reconciliation.
Primary sources
Want to see how Recipe Scaling with Potency could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
